Back to all assets

Charles River Laboratories CRL

equity

Price History

$21.38$163.81$306.24$448.68
2000-06 · DCA start$22.19

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-73.6%-49.0%-24.5%0.0%
2000-062026-08 · -36.6%

Worst drawdown: −74%, peaking Oct 2021 and bottoming Apr 2025 — still unrecovered after 58 months.

DCA Backtest

Invested
$31,500
Value today
$159,302
Return
+405.7%
Months invested
315

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $45,666 today, so the real (inflation-adjusted) return is +248.8%.

Lump sum instead — $31,500 all at once in Jun 2000: $403,725 (+1181.7%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Oct 2021): $8,225 on $5,900 invested (+39.4%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 2000-06: +405.7%

About Charles River Laboratories

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients. (Wikipedia)

It's a listed company categorised under health care and life sciences tools & services, with a market cap of about $13.6B.

It rates High Risk at 3.2/5, meaning several rated factors score badly, so this carries materially more risk than a typical holding.

What pushes the score up: earnings quality (5.0/5) and market / volatility (3.7/5).

Scoring well: liquidity at 1.0/5.

Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

High Risk(3.2/5)80% rated

How these ratings work

Market / Volatility3.7/5 · weight 20%
  • Annualised volatility (3yr)4/543.2
  • Max drawdown from ATH4/573.6
  • Beta vs S&P 5003/51.0
Liquidity1.0/5 · weight 15%
  • Avg daily $ volume1/5190.1m
  • Float % of shares outstandingnot yet researched
Leverage / Financial3.0/5 · weight 20%
  • Debt / equity3/50.92
  • Interest coverage (EBIT / interest)not yet researched
Earnings Quality5.0/5 · weight 15%
  • 3yr EPS volatility5/5100
Concentrationunrated · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentrationnot yet researched
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.